Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A. The intellectual property that Cassava has licensed is based on the promising research and development ...
Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback